A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2010
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease; Huntington's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 31 Dec 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
- 31 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.